Glucagon‐like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta‐analysis of randomised controlled trials.

Silverii, Giovanni Antonio; Pala, Laura; Cresci, Barbara; Mannucci, Edoardo

The meta-analysis examined the association between GLP-1 receptor agonists and the risk of ischemic optic neuropathy in patients with obesity and/or type 2 diabetes. While some observational studies suggested a potential link, the meta-analysis of randomized controlled trials did not find a significant detrimental effect of GLP-1 RA therapy on optic neuropathy. The estimated incidence of optic ischemic neuropathy was higher in the GLP-1 RA arm compared to the placebo arm, but the difference was not statistically significant. Further research is needed to fully understand the safety profile of GLP-1 RA, especially in patients at higher risk for optic neuropathy.

GLUCAGON-like peptide-1 agonists; OPTIC nerve; NEUROPATHY; OBESITY; TYPE 2 diabetes; DRUG side effects

Diabetes, Obesity & Metabolism, 2025, Vol 27, Issue 2, p1005

1462-8902

Academic Journal

10.1111/dom.16076